Reaction
Inflammatory Carcinoma Of The Breast reporting signals
As of the last recalculation, Inflammatory Carcinoma Of The Breast appears in 145 FAERS reports alongside 2 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 88.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 5 | 88.1 | 88.2 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 10 | 65.2 | 65.3 |